Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion

被引:0
|
作者
Zhang, Siya [1 ,2 ]
Wang, Hong-Yin [3 ]
Tao, Xuan [4 ]
Chen, Zhongwen [5 ]
Levental, Ilya [3 ]
Lin, Xubo [1 ]
机构
[1] Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Sch Engn Med, Beijing 100191, Peoples R China
[2] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100005, Peoples R China
[3] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22903 USA
[4] Tsinghua Univ, Sch Life Sci, State Key Lab Membrane Biol, Beijing 100084, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Organ Chem, Interdisciplinary Res Ctr Biol & Chem, Shanghai 201210, Peoples R China
基金
美国国家卫生研究院; 中国国家自然科学基金;
关键词
CANCER-IMMUNOTHERAPY; DYNAMICS; SIMULATIONS; MODULATE; PHASE;
D O I
10.1021/acs.langmuir.4c04441
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Recently identified palmitoylation of PD-L1 is essential for immune regulation. To elucidate the underlying molecular mechanism, we performed giant plasma membrane vesicle (GPMV) experiments, mu s-scale all-atom molecular dynamics (MD) simulations, fluorescence resonance energy transfer (FRET) experiments, and immune killing experiments. GPMV experiments indicated that PD-L1 palmitoylation enhanced its lipid raft affinity. MD simulations revealed dramatically different membrane orientation states of PD-L1 in liquid-ordered (L o, lipid raft) compared to liquid-disordered (L d, nonraft) membrane environments, which was validated by FRET experiments. The L d region promoted the "lie-down" orientation of PD-L1, which could inhibit its association with the PD-1 protein on immune cells and thus promote the immune killing of cancer cells. This hypothesis was supported by immune killing experiments using gamma delta T cells as effector cells and NCI-H1299 lung cancer cells as target cells. In short, our study demonstrates that the palmitoylation affects PD-L1's membrane localization and then membrane orientation, which thus regulates its binding with T cell PD-1 and the immune regulation. These observations may guide therapeutic strategies by explicating the regulation of immune checkpoint proteins by post-translational modifications and membrane environments.
引用
收藏
页码:5170 / 5178
页数:9
相关论文
共 50 条
  • [1] The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
    Berry, Diana
    Moldoveanu, Dan
    Rajkumar, Shivshankari
    Lajoie, Mathieu
    Lin, Tiffany
    Tchelougou, Damehan
    Sakthivel, Samridhi
    Sharon, Itai
    Bernard, Antoine
    Pelletier, Sandy
    Ripstein, Yael
    Spatz, Alan
    Miller, Wilson H.
    Jamal, Rahima
    Lapointe, Rejean
    Mes-Masson, Anne-Marie
    Petrecca, Kevin
    Meguerditchian, Ari-Nareg
    Richardson, Keith
    Wang, Beatrice
    Chergui, May
    Guiot, Marie-Christine
    Watters, Kevin
    Stagg, John
    Schmeing, T. Martin
    Rodier, Francis
    Turcotte, Simon
    Mihalcioiu, Catalin
    Meterissian, Sarkis
    Watson, Ian R.
    CELL REPORTS, 2025, 44 (03):
  • [2] αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
    Vannini, Andrea
    Leoni, Valerio
    Barboni, Catia
    Sanapo, Mara
    Zaghini, Anna
    Malatesta, Paolo
    Campadelli-Fiume, Gabriella
    Gianni, Tatiana
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (40) : 20141 - 20150
  • [3] PD-1/PD-L1 expression in colorectal cancer and its implications for apoptosis and tumor immune evasion
    Gasser, Martin
    Grimm, Martin
    Nichiporuk, Ekaterina
    Bueter, Marco
    Lutz, Jens
    Lebedeva, Tatiana
    Koenigshausen, Matthias
    Thalheimer, Andreas
    Thiede, Arnulf
    Heemann, Uwe
    Meyer, Detlef
    Waaga-Gasser, Ana Maria
    CANCER RESEARCH, 2006, 66 (08)
  • [4] RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion
    Glodde, Nicole
    Hoelzel, Michael
    IMMUNITY, 2017, 47 (06) : 1007 - 1009
  • [5] Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers
    Prodeus, Aaron
    Gariepy, Jean
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [6] Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
    Wang, Yiting
    Wang, Huanbin
    Yao, Han
    Li, Chushu
    Fang, Jing-Yuan
    Xu, Jie
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [7] IMMUNE EVASION MEDIATED BY PD-L1 ON GLIOBLASTOMA DERIVED EXTRACELLULAR VESICLES
    Ricklefs, F. L.
    Speranza, M. C.
    Hayes, J.
    Balaj, L.
    Breakefield, X. O.
    Bronisz, A.
    Carter, B.
    Freeman, G.
    Lawler, S.
    Chiocca, E. A.
    NEURO-ONCOLOGY, 2017, 19 : 50 - 50
  • [8] Extracellular Vesicles Containing PD-L1 Contribute to Immune Evasion in Glioblastoma
    Lubin, Jonathan A.
    Zhang, Ray R.
    Kuo, John S.
    NEUROSURGERY, 2018, 83 (03) : E98 - E100
  • [9] The emerging roles of PD-L1 subcellular localization in tumor immune evasion
    Liu, Dandan
    Wen, Chengcai
    Chen, Lu
    Ye, Mao
    Liu, Hong
    Sun, Xing
    Liang, Long
    Zhang, Ji
    Chang, Shi
    Liu, Jing
    BIOCHEMICAL PHARMACOLOGY, 2024, 220
  • [10] Novel mechanism of immune evasion involving PD-L1 in various cancers
    Kataoka, Keisuke
    Ogawa, Seishi
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S928 - S929